Valeant Pharmaceuticals Intl Inc. Is at the Mercy of its Lenders

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is trying to get its debt covenants relaxed. Penn West Petroleum Ltd. (TSX:PWT)(NYSE:PWE) has shown that this can be painful.

| More on:
The Motley Fool

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is in danger of defaulting on its debt, which would be yet another catastrophe for shareholders. To save itself from that fate, it is currently negotiating with its lenders to ease covenants.

But this has consequences too, as has been demonstrated by a number of oil companies. Penn West Petroleum Ltd. (TSX:PWT)(NYSE:PWE) is one example. We’ll take a closer look below.

Valeant’s covenants

According to Valeant’s credit agreement, a default will occur if Valeant doesn’t file its 10-K (which includes audited financial statements) by the end of this month. In that scenario, Valeant will then have 30 days to cure the default by filing its 10-K.

Meanwhile, Valeant has already breached the reporting covenant in its bond indentures, which required a 10-K by March 16. As a result, the company is restricted from borrowing any more money from its revolver.

These aren’t the only covenants Valeant must adhere to; there are also certain financial targets that the company must maintain. The company said it expects to be in compliance with all covenants this year and next, but until the company releases audited financials, it’s impossible to know for sure.

Penn West’s experience

At the beginning of last year Penn West was about to breach its debt covenants, which would have meant a default. To avoid such a fate, the company got lenders to relax covenants. And even though an agreement was reached, it was not a fun process.

For starters, Penn West had to lower its quarterly dividend from $0.03 to $0.01. The company also had to cancel a $500 million tranche in its bank facility. It also had to grant floating charge security over all its property. If that wasn’t bad enough, Penn West had to pledge that any asset sales would go towards reducing debt. To top it all off, the company had to agree to higher interest payments.

Anything can happen

This situation with Valeant is a little different, because Valeant hasn’t even released audited financials, making the outcome very unpredictable. Otherwise, Penn West’s experience provides a useful learning experience.

And anonymous sources have already told Reuters that “creditors prepare to slam company with tougher demands” in exchange for relaxing covenants. So one way or another, Valeant is in for a rough ride. This story is far from over.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Benjamin Sinclair has no position in any stocks mentioned.  Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

young woman celebrating a victory while working with mobile phone in the office
Investing

3 Roaring Stocks to Hold for the Next 20 Years

These top TSX stocks are excellent long-term buys, given their multi-year growth potential and solid underlying businesses.

Read more »

Two seniors float in a pool.
Dividend Stocks

TFSA: How to Earn $1,890 in Annual Tax-Free Income

Plunk these investments into your TFSA to earn passive income and avoid the taxman.

Read more »

grow dividends
Investing

Here’s My Top 3 TSX Stocks to Buy Right Now

Even though the TSX has been rising, there are still some good bargains out there. Here are three top compounding…

Read more »

Target. Stand out from the crowd
Investing

Prediction: This Canadian Growth Stock Could Double by 2030

Alimentation Couche-Tard (TSX:ATD) is a top growth stock that could do well over the next six or so years.

Read more »

Businessman holding AI cloud
Tech Stocks

Could Investing $20,000 in Nvidia Make You a Millionaire?

Nvidia stock has made investors millionaires in the last 10 years. Is it too late to invest to become a…

Read more »

Engineers walk through a facility.
Dividend Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

AtkinsRéalis (TSX:ATRL) is one TSX stock I'd never invest in.

Read more »

money cash dividends
Stocks for Beginners

Have $500? 3 Absurdly Cheap Stocks Long-Term Investors Should Buy Right Now

If you're looking for cheap stocks, these three have a huge future ahead of them, all while costing far less…

Read more »